Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

被引:138
作者
Al-Mansour, Mubarak
Connors, Joseph M.
Gascoyne, Randy D.
Skinnider, Brian
Savage, Kerry J. [1 ]
机构
[1] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
关键词
B-CELL LYMPHOMA; NATIONAL-CANCER-INSTITUTE; CLINICAL-TRIALS GROUP; EUROPEAN TASK-FORCE; PHASE-II; DISEASE; REGIMEN; CHEMOTHERAPY; PARAGRANULOMA; REVEALS;
D O I
10.1200/JCO.2009.24.9516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Prior observations suggest a higher risk of transformation of nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), than in classical Hodgkin's lymphoma. We evaluated the frequency of transformation in all patients diagnosed with NLPHL at the British Columbia Cancer Agency with long-term follow-up. Patients and Methods The Lymphoid Cancer Database of the British Columbia Cancer Agency was searched to identify all patients diagnosed with NLPHL between 1965 and 2006. After pathologic review, 95 patients with NLPHL were confirmed. Results Patients with NLPHL had the following characteristics at diagnosis: median age of 37 years, 73% male, and 68% stage I or II disease. With a median follow-up time for living patients of 6.5 years (range, 2.5 to 33 years), 13 patients (14%) experienced transformation to aggressive lymphoma (median time to transformation, 8.1 years; range, 0.35 to 20.3 years). The actuarial risk of transformation to aggressive lymphoma was 7% and 30% at 10 and 20 years, respectively. Transformation was more likely in patients with initial splenic involvement (P = .006) at the time of diagnosis of NLPHL. The 10-year progression-free and overall survival rates in patients with transformed lymphoma were 52% and 62%, respectively. Conclusion The risk of transformation in patients with NLPHL to DLBCL is substantial and underappreciated. Because transformation can occur years after the primary diagnosis of NLPHL, long-term follow-up of these individuals is necessary to accurately estimate the risk of development of secondary DLBCL.
引用
收藏
页码:793 / 799
页数:7
相关论文
共 37 条
[1]   Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma [J].
Al-Tourah, Abdulwahab J. ;
Gill, Karamjit K. ;
Chhanabhai, Mukesh ;
Hoskins, Paul J. ;
Klasa, Richard J. ;
Savage, Kerry J. ;
Sehn, Laurie H. ;
Shenkier, Tamara N. ;
Gascoyne, Randy D. ;
Connors, Joseph M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5165-5169
[2]  
Anagnostopoulos I, 2000, BLOOD, V96, P1889
[3]   Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].
Baetz, T ;
Belch, A ;
Couban, S ;
Imrie, K ;
Yau, J ;
Myers, R ;
Ding, K ;
Paul, N ;
Shepherd, L ;
Iglesias, J ;
Meyer, R ;
Crump, M .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767
[4]   NON-HODGKINS-LYMPHOMA ARISING IN PATIENTS TREATED FOR HODGKINS-DISEASE IN THE BNLI - A 20-YEAR EXPERIENCE [J].
BENNETT, MH ;
MACLENNAN, KA ;
HUDSON, GV ;
HUDSON, BV .
ANNALS OF ONCOLOGY, 1991, 2 :83-92
[5]   Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease [J].
Bodis, S ;
Kraus, MD ;
Pinkus, G ;
Silver, B ;
Kadin, ME ;
Canellos, GP ;
Shulman, LN ;
Tarbell, NJ ;
Mauch, PM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3060-3066
[6]   Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma:: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma [J].
Boudová, L ;
Torlakovic, E ;
Delable, J ;
Reimer, P ;
Pfistner, B ;
Wiedenmann, S ;
Diehl, V ;
Müller-Hermelink, HK ;
Rüdiger, T .
BLOOD, 2003, 102 (10) :3753-3758
[7]   Primary mediastinal large B-cell lymphoma - A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (''Groupe d'Etude des Lymphomes de L'adulte'') study [J].
CazalsHatem, D ;
Lepage, E ;
Brice, P ;
Ferrant, A ;
dAgay, MF ;
Baumelou, E ;
Briere, J ;
Blanc, M ;
Gaulard, P ;
Biron, P ;
Schlaifer, D ;
Diebold, J ;
Audouin, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (07) :877-888
[8]   FURTHER PHENOTYPIC EVIDENCE THAT NODULAR, LYMPHOCYTE-PREDOMINANT HODGKINS-DISEASE IS A LARGE B-CELL LYMPHOMA IN EVOLUTION [J].
CHITTAL, SM ;
ALARD, C ;
ROSSI, JF ;
ALSAATI, T ;
LETOURNEAU, A ;
DIEBOLD, J ;
DELSOL, G .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (11) :1024-1035
[9]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[10]   Treatment of advanced Hodgkin's disease with chemotherapy - Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group [J].
Connors, JM ;
Klimo, P ;
Adams, G ;
Burns, BF ;
Cooper, I ;
Meyer, RM ;
OReilly, SE ;
Pater, J ;
Quirt, I ;
Sadura, A ;
Shustik, C ;
Skillings, J ;
Sutcliffe, S ;
Verma, S ;
Yoshida, S ;
Zee, B .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1638-1645